HYPOPHOSPHATASIA
Clinical trials for HYPOPHOSPHATASIA explained in plain language.
Never miss a new study
Get alerted when new HYPOPHOSPHATASIA trials appear
Sign up with your email to follow new studies for HYPOPHOSPHATASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to strengthen bones in kids with rare genetic disorder
Disease control OngoingThis study is testing whether an experimental drug called ALXN1850 can improve bone health and physical abilities in children aged 2-12 with hypophosphatasia, a rare genetic condition that weakens bones. Participants receive either the drug or a placebo through injections under t…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for kids with rare bone disease: testing Next-Generation treatment
Disease control OngoingThis study is testing a new drug called ALXN1850 against the current standard treatment (asfotase alfa) in children aged 2 to under 12 who have a rare bone-weakening condition called hypophosphatasia (HPP). The main goal is to see if the new drug is as safe and well-tolerated as …
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Fixing a broken treatment: new approach for rare bone disease
Disease control TerminatedThis study aimed to help patients with hypophosphatasia, a rare bone disorder, who started responding to their main treatment (asfotase alfa) but then lost that benefit. Researchers planned to test if adding immune-suppressing drugs could restore the treatment's effectiveness in …
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial aims to help people walk farther, hurt less from rare bone disease
Disease control OngoingThis study is testing whether a new drug called ALXN1850 can improve walking ability, strength, and reduce pain in teenagers and adults with hypophosphatasia, a rare genetic bone disorder. Participants who have never taken the existing treatment (asfotase alfa) will receive eithe…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC